Gilbert Richard E, Mende Christian, Vijapurkar Ujjwala, Sha Sue, Davies Michael J, Desai Mehul
St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
University of California, San Diego, La Jolla, CA, USA.
Diabetes Ther. 2017 Apr;8(2):451-458. doi: 10.1007/s13300-017-0232-0. Epub 2017 Feb 14.
The objective of this study was to evaluate the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on serum magnesium in hypomagnesemic patients with type 2 diabetes.
This post hoc analysis was based on pooled data from four placebo-controlled studies of canagliflozin (N = 2313). The proportion of patients with baseline serum magnesium <0.74 mmol/L who achieved serum magnesium ≥0.74 mmol/L at week 26 was evaluated.
At week 26, canagliflozin 100 and 300 mg increased serum magnesium versus placebo in patients with baseline serum magnesium <0.74 mmol/L (17.0% and 19.0% vs 3.9%) and ≥0.74 mmol/L (4.9% and 7.0% vs -1.4%). More patients with baseline serum magnesium <0.74 mmol/L had serum magnesium ≥0.74 mmol/L at week 26 with canagliflozin 100 and 300 mg versus placebo (74.1% and 80.6% vs 28.8%).
Canagliflozin was associated with normalization of serum magnesium in hypomagnesemic patients with type 2 diabetes, potentially leading to improved cardiometabolic outcomes.
ClinicalTrials.gov Identifiers, NCT01081834, NCT01106677, NCT01106625, NCT01106690.
本研究的目的是评估钠-葡萄糖协同转运蛋白2抑制剂卡格列净对2型糖尿病低镁血症患者血清镁的影响。
本事后分析基于四项卡格列净安慰剂对照研究（N = 2313）的汇总数据。评估了基线血清镁<0.74 mmol/L的患者在第26周时血清镁≥0.74 mmol/L的比例。
在第26周时，对于基线血清镁<0.74 mmol/L的患者，卡格列净100 mg和300 mg组血清镁较安慰剂组升高（分别为17.0%和19.0%，而安慰剂组为3.9%）；对于基线血清镁≥0.74 mmol/L的患者，卡格列净100 mg和300 mg组血清镁较安慰剂组升高（分别为4.9%和7.0%，而安慰剂组为-1.4%）。与安慰剂相比，基线血清镁<0.74 mmol/L的患者在第26周时使用卡格列净100 mg和300 mg后血清镁≥0.74 mmol/L的更多（分别为74.1%和80.6%，而安慰剂组为28.8%）。
卡格列净与2型糖尿病低镁血症患者血清镁正常化相关联，可能会改善心脏代谢结局。
ClinicalTrials.gov标识符，NCT01081834、NCT01106677、NCT01106625、NCT01106690。
